Abstract Library

#4431 Systemic treatment in metastatic pheochromocytomas and paragangliomas: Optimal moment for starting and outcomes of a multicentre Spanish cohort

Introduction: Pheochromocytomas (PHEOs) and paragangliomas (PGLs), collectively referred to as PPGLs, are relatively rare endocrine tumours with significant clinical variability and metastatic behaviour. Treatment strategies must be tailored individually due to the heterogeneity in their behaviour.

Conference:

Presenting Author: Del Olmo-García M

Authors: Hernández-Rienda L, Contreras-Saldarriaga J, Hernando Cubero J, García Alvarez A, Prado-Wohlwend S,

Keywords: Pheochromocytoma, paraganglioma, PPGL, metastatic, SSA, Radionuclide, chemotherapy,

#4386 Streptozotocin- and temozolomide-based chemotherapy treatment in neuroendocrine neoplasms – Efficacy in patients treated outside clinical trials

Introduction: Chemotherapy treatment based on alkylating agents is useful in pancreatic and grade 3 neuroendocrine neoplasms (NENs). However, no current real-life data is available comparing streptozotocin (STZ) and temozolomide (TEM) combinations.

Conference:

Presenting Author: García-Álvarez A

Authors: García Alvarez A, Martínez-Badal S, García-Burillo A, Simó Perdigo M, Merino Casabiel X,

Keywords: Streptozotocin, temozolomide, neuroendocrine neoplasm,

#4352 What can a reference centre offer to patients? Evolution of first visits for neuroendocrine and endocrine tumours and its relation to clinical trials availability.

Introduction: Endocrine and neuroendocrine neoplasia (NEN), which include gastroenteropancreatic neuroendocrine tumours, thyroid cancer and adrenal carcinoma, have a low incidence, making their diagnosis and treatment difficult. Due to this complexity, patients should be managed at specialised centres; however, the lack of official referral networks complicates the concentration of cases.

Conference:

Presenting Author: Martinez-Badal S

Authors: Martínez-Badal S, Hernando Cubero J, García Alvarez A, Elguero B, Alcantara A,

Keywords: Neuroendocrine, Clinical Trial, Reference Centre, Patient referral,

#4174 Uncovering the genomic profiling of metastatic pheochromocytomas and paragangliomas: Leveraging plasma circulating tumor DNA for comprehensive genetic characterisation and monitoring

Introduction: Liquid biopsy, notably plasma circulating tumor DNA (ctDNA), is a non-invasive approach to elucidate the tumoral genomic profile from a blood sample. Pheochromocytomas and paragangliomas (PPGL) are often operated, characterized by quiet genomes and usually indolent tumor growth. However, challenges arise with metastatic tumors due to accessibility, catecholamine-related crises and surgery issues. Thus, molecular mechanisms transitioning from indolent to metastatic tumors are largely unexplored.

Conference:

Presenting Author:

Authors: Arenillas Lallana C, Moreno-Cárdenas A, Casteràs A, García-Álvarez A, Hernando J,

Keywords: liquid biopsy, ctDNA, metastasis, pheochromocytoma, paraganglioma, genomic targets,

#4125 Durvalumab (D) plus Tremelimumab (T) for the treatment of patients with progressive, advanced medullary thyroid carcinoma (MTC) – DUTHY (GETNE-T1812) trial

Introduction: Evidence for immunotherapy (IT) in patients (pts) with MTC is limited and has shown modest activity.

Conference:

Presenting Author:

Authors: García-Álvarez A, Molina-Cerrillo J, Castelo B, Plana M, Iglesias L,

Keywords: Medullary thyroid carcinoma, Immunotherapy, durvalumab, tremelimumab, anti PD-L1, anti CTLA-4,